Table 4. Subgroup analyses for the impact of elevated plasma fibrinogen levels on prognosis of EOC.

Category		No. of studies with references	HR	95% CI	Heterogeneity		Model
					p-value	I2
PFS
Adjustment for potential confounding factors
	Adjuvant chemotherapy, age, FIGO stage, grade, residual tumor size	3	1.467	1.145–1.880	0.657	0.000	Fixed effect
	Age, CA-125, FIGO stage, grade, histology, NLR, PLR, residual tumor size	2	1.568	1.195–2.056	0.444	0.000	Fixed effect
	Adjuvant chemotherapy, age, FIGO stage, grade, histology, neoadjuvant chemotherapy, residual tumor size	2	1.352	1.005–1.836	0.827	0.000	Fixed effect
OS
Quality of study (NOS)
	9	3	1.718	1.094–2.698	0.087	0.591	Random effects
Adjustment for potential confounding factors
	Adjuvant chemotherapy, age, FIGO stage, grade, residual tumor size	3	1.718	1.094–2.698	0.087	0.591	Random effects
	Age, CA-125, FIGO stage, grade, histology, NLR, PLR, residual tumor size	2	1.610	1.238–3.405	0.015	0.830	Random effects
	Adjuvant chemotherapy, age, FIGO stage, grade, histology, neoadjuvant chemotherapy, residual tumor size	2	1.537	1.231–3.111	0.051	0.737	Random effects

CI, confidence interval; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; NLR, neutrophil to lymphocyte ratio; NOS, the Newcastle-Ottawa Scale; PFS, progression-free survival; PLR, platelet to lymphocyte ratio.